Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19355664 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TP53MMESMN1; SMN2PLA2G2A | |
| SCHEMBL3677560 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TP53MMESMN1; SMN2PLA2G2A | |
| SCHEMBL10207210 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TP53MMESMN1; SMN2PLA2G2A | |
| SCHEMBL1319707 | 0.83 | SMN1; SMN2 (0.44) | ALDH1A1TP53SMN1; SMN2PLA2G2APLA2G5 | |
| SCHEMBL27282795 | 0.83 | ALDH1A1 (0.36) | ALDH1A1TP53SMN1; SMN2PLA2G2APLA2G5 | |
| SCHEMBL1319709 | 0.83 | SMN1; SMN2 (0.44) | ALDH1A1TP53SMN1; SMN2PLA2G2APLA2G5 | |
| SCHEMBL5015591 | 0.82 | SMN1; SMN2 (0.41) | ALDH1A1TP53MMESMN1; SMN2PLA2G2A | |
| SCHEMBL5015593 | 0.82 | SMN1; SMN2 (0.41) | ALDH1A1TP53MMESMN1; SMN2PLA2G2A | |
| SCHEMBL24593933 | 0.81 | KISS1R (0.31) | — | |
| Hydrochloric Acid SCHEMBL873158 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1TP53SMN1; SMN2PLA2G2APLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732002-B2 | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-22 | — | — | US | disclosed |
| EP-2195009-B1 | CYCLIC UNDECAPEPTIDES AND DERIVATIVES AS MULTIPLE SCLEROSIS THERAPIES | UNIV OREGON HEALTH & SCIENCE (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8394763-B2 | Cyclic undecapeptides and derivatives as multiple sclerosis therapies | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2013-03-12 | — | — | US | disclosed |
| US-20100196317-A1 | CYCLIC UNDECAPEPTIDES AND DERIVATIVES AS MULTIPLE SCLEROSIS THERAPIES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA D.B.A. THE DEPARTMENT OF VETERANS AFFAIRS | 2010-08-05 | — | — | US | disclosed |
| EP-2195009-A1 | CYCLIC UNDECAPEPTIDES AND DERIVATIVES AS MULTIPLE SCLEROSIS THERAPIES | Oregon Health and Science University (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-1677816-A4 | THERAPEUTIC METHOD | UNIV MONASH (AU) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009042892-A1 | CYCLIC UNDECAPEPTIDES AND DERIVATIVES AS MULTIPLE SCLEROSIS THERAPIES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20080188079-A1 | METAL-POLISHING COMPOSITION AND CHEMICAL MECHANICAL POLISHING METHOD BY USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-08-07 | — | — | US | disclosed |
| EP-1677816-A1 | THERAPEUTIC METHOD | MONASH UNIVERSITY (AU) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005032578-A1 | THERAPEUTIC METHOD | MONASH UNIVERSITY (AU) | 2005-04-14 | — | — | WO | disclosed |
| EP-1395661-A2 | PROCESS FOR THE PREPARATION OF D-PANTOTHENIC ACID AND/OR SALTS THEREOF | Degussa AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002101068-A2 | PROCESS FOR THE PREPARATION OF D-PANTOTHENIC ACID AND/OR SALTS THEREOF | DEGUSSA AG (DE) | 2002-12-19 | — | — | WO | disclosed |
| EP-1084247-A1 | DISULFIDE CORE POLYPEPTIDES | ZymoGenetics, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999063091-A1 | DISULFIDE CORE POLYPEPTIDES | ZYMOGENETICS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0813544-A4 | — | — | 1998-01-07 | — | — | EP | disclosed |
| EP-0813544-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1995024422-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11732002-B2 | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound | VIP, PEPD, MLN | ALDH1A1 4602/4885TP53 3451/4885MME 85/4885 |
| US-20100196317-A1 | CYCLIC UNDECAPEPTIDES AND DERIVATIVES AS MULTIPLE SCLEROSIS THERAPIES | PMP22, CX3CR1, VIP | ALDH1A1 4590/4885TP53 4285/4885MME 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.